Suppr超能文献

用于重大骨科手术的新型抗血栓药物与神经轴索麻醉:管理策略

Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies.

作者信息

Rosencher N, Bonnet M-P, Sessler D I

机构信息

Department of Anaesthesiology and Intensive Care, Groupe Hospitalier Cochin Port Royal, Assistance Publique - Hôpitaux de Paris, Université René Descartes (Paris 5), Paris, France.

出版信息

Anaesthesia. 2007 Nov;62(11):1154-60. doi: 10.1111/j.1365-2044.2007.05195.x.

Abstract

We propose recommendations to reduce the risk of haemorrhagic events associated with regional anaesthesia in patients treated with newer anticoagulants after orthopaedic surgery. The risk/benefit ratio should be individualised for each patient according to the type and dose of anticoagulant, the type of regional anaesthesia and patient risk factors. Neuraxial anaesthetic management strategy can be based on the pharmacokinetic properties of specific anticoagulants, including the time required to reach maximal concentration, half-life, and dose regimen. Central neuraxial blocks should not be performed and epidural catheters should not be removed until at least two half-lives after the last injection of anticoagulant, the half-life depending on renal function. After removing a catheter or after a haemorrhagic puncture, the timing of the next anticoagulant injection should be based on the time required for an anticoagulant dose to reach maximum activity. Vigilance remains paramount during the initial days after removal of a neuraxial catheter.

摘要

我们提出了一些建议,以降低接受新型抗凝剂治疗的骨科手术后患者发生与区域麻醉相关的出血事件的风险。应根据抗凝剂的类型和剂量、区域麻醉的类型以及患者风险因素,为每位患者个体化确定风险/获益比。神经轴麻管理策略可基于特定抗凝剂的药代动力学特性,包括达到最大浓度所需的时间、半衰期和给药方案。在最后一次注射抗凝剂至少两个半衰期后(半衰期取决于肾功能),不应进行中枢神经轴阻滞,也不应拔除硬膜外导管。拔除导管后或发生出血性穿刺后,下次抗凝剂注射的时间应基于抗凝剂剂量达到最大活性所需的时间。在拔除神经轴导管后的最初几天,警惕性仍然至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验